Literature DB >> 11022230

Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells.

J W Zhang1, J Y Wang, S J Chen, Z Chen.   

Abstract

Retinoic acids (RA) play a key role in myeloid differentiation through their agonistic nuclear receptors (RAR alpha/RXR) to modulate the expression of target genes. In acute promyelocytic leukemia (APL) cells with rearrangement of retinoic acid receptor a (RAR alpha) (including: PML-RAR alpha, PLZF-RAR alpha, NPM-RAR alpha, NuMA- RAR alpha or STAT5b-RAR alpha) as a result of chromosomal translocations, the RA signal pathway is disrupted and myeloid differentiation is arrested at the promyelocytic stage. Pharmacologic dosage of all-trans retinoic acid (ATRA) directly modulates PML-RAR alpha and its interaction with the nuclear receptor co-repressor complex, which restores the wild-type RAR alpha/RXR regulatory pathway and induces the transcriptional expression of downstream genes. Analysing gene expression profiles in APL cells before and after ATRA treatment represents a useful approach to identify genes whose functions are involved in this new cancer treatment. A chronologically well coordinated modulation of ATRA-regulated genes has thus been revealed which seems to constitute a balanced functional network underlying decreased cellular proliferation, initiation and progression of maturation, and maintenance of cell survival before terminal differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022230     DOI: 10.1007/BF02703936

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   2.795


  80 in total

Review 1.  Increasing the complexity of coactivation in nuclear receptor signaling.

Authors:  L P Freedman
Journal:  Cell       Date:  1999-04-02       Impact factor: 41.582

2.  A novel, myeloid transcription factor, C/EBP epsilon, is upregulated during granulocytic, but not monocytic, differentiation.

Authors:  R Morosetti; D J Park; A M Chumakov; I Grillier; M Shiohara; A F Gombart; T Nakamaki; K Weinberg; H P Koeffler
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

3.  Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable.

Authors:  S C Kogan; S H Hong; D B Shultz; M L Privalsky; J M Bishop
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

4.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

Authors:  P Fenaux; C Chastang; S Chevret; M Sanz; H Dombret; E Archimbaud; M Fey; C Rayon; F Huguet; J J Sotto; C Gardin; P C Makhoul; P Travade; E Solary; N Fegueux; D Bordessoule; J S Miguel; H Link; B Desablens; A Stamatoullas; E Deconinck; F Maloisel; S Castaigne; C Preudhomme; L Degos
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

5.  Functional inhibition of retinoic acid response by dominant negative retinoic acid receptor mutants.

Authors:  K Damm; R A Heyman; K Umesono; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

6.  Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element.

Authors:  P Leroy; H Nakshatri; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

7.  Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells.

Authors:  K A Robertson; B Emami; L Mueller; S J Collins
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

8.  Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

Authors:  R P Warrell; L Z He; V Richon; E Calleja; P P Pandolfi
Journal:  J Natl Cancer Inst       Date:  1998-11-04       Impact factor: 13.506

9.  Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha).

Authors:  S J Collins; K A Robertson; L Mueller
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

10.  PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR.

Authors:  A Perez; P Kastner; S Sethi; Y Lutz; C Reibel; P Chambon
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

View more
  14 in total

1.  Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells.

Authors:  Lei Zhang; Yan Yan; Difeng Zhu; Wei Yang; Weisi Wang; Yongzhou Hu; Bo Yang; Qiaojun He
Journal:  Invest New Drugs       Date:  2010-08-05       Impact factor: 3.850

2.  Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells.

Authors:  Y Yan; E A Hanse; K Stedman; J M Benson; X H Lowman; S Subramanian; A Kelekar
Journal:  Cell Death Differ       Date:  2016-02-12       Impact factor: 15.828

Review 3.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Authors:  Marilyn M Li; Michael Datto; Eric J Duncavage; Shashikant Kulkarni; Neal I Lindeman; Somak Roy; Apostolia M Tsimberidou; Cindy L Vnencak-Jones; Daynna J Wolff; Anas Younes; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-01       Impact factor: 5.568

4.  Retinoid levels influence enterohemorrhagic Escherichia coli infection and Shiga toxin 2 susceptibility in mice.

Authors:  Gabriel Cabrera; Romina J Fernández-Brando; María Jimena Abrey-Recalde; Ariela Baschkier; Alipio Pinto; Jorge Goldstein; Elsa Zotta; Roberto Meiss; Marta Rivas; Marina S Palermo
Journal:  Infect Immun       Date:  2014-07-07       Impact factor: 3.441

5.  A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.

Authors:  Kimberly B Higginbotham; Richard Lozano; Thomas Brown; Yehuda Z Patt; Takashi Arima; James L Abbruzzese; Melanie B Thomas
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-27       Impact factor: 4.553

6.  DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.

Authors:  Eric Haines; Yuki Nishida; Michael Andreeff; Lyubomir T Vassilev; Michael I Carr; Rafael Heinz Montoya; Lauren B Ostermann; Weiguo Zhang; Frank T Zenke; Andree Blaukat
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

7.  Studies on Multifunctional Effect of All-Trans Retinoic Acid (ATRA) on Matrix Metalloproteinase-2 (MMP-2) and Its Regulatory Molecules in Human Breast Cancer Cells (MCF-7).

Authors:  Anindita Dutta; Triparna Sen; Aniruddha Banerji; Shamik Das; Amitava Chatterjee
Journal:  J Oncol       Date:  2009-07-19       Impact factor: 4.375

8.  Two cases of differentiation syndrome with ocular manifestations in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and arsenic trioxide.

Authors:  A R Newman; B Leung; A Richards; T G Campbell; J Wellwood; F R Imrie
Journal:  Am J Ophthalmol Case Rep       Date:  2018-01-17

9.  Differentiation therapy of acute myeloid leukemia.

Authors:  Elzbieta Gocek; Ewa Marcinkowska
Journal:  Cancers (Basel)       Date:  2011-05-16       Impact factor: 6.639

10.  Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.

Authors:  Chong Chen; Yu Liu; Chao Lu; Justin R Cross; John P Morris; Aditya S Shroff; Patrick S Ward; James E Bradner; Craig Thompson; Scott W Lowe
Journal:  Genes Dev       Date:  2013-09-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.